Core Laboratories (NYSE: CLB) director gets 7,895 restricted shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Core Laboratories director Temeng Kwaku reported equity compensation and an option-style exercise. On April 1, 2026, he received a grant of 7,895 Restricted Shares that will vest after a one-year period ending on April 1, 2027, subject to the terms of issuance and a deferral election under Treasury Regulation 1.409A-2.

The filing also shows 8,069 Restricted Shares vested after a one-year period ending April 1, 2026 and were exercised into 8,069 shares of Common Stock at no cash exercise price. Following these transactions, Kwaku directly holds 33,597 shares of Core Laboratories Common Stock.

Insider Trade Summary

8,069 shares exercised/converted

Mixed 3 txns

Insider Temeng Kwaku

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Shares	7,895	$0.00	--
Exercise	Restricted Shares	8,069	$0.00	--
Exercise	Common Stock	8,069	$0.00	--

Holdings After Transaction: Restricted Shares — 7,895 shares (Direct); Common Stock — 33,597 shares (Direct)

Footnotes (1)

The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board. The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.

Key Figures

Restricted Shares granted: 7,895 shares Restricted Shares exercised: 8,069 shares Common Stock holdings after transactions: 33,597 shares +1 more

4 metrics

Restricted Shares granted 7,895 shares Award of Restricted Shares vesting April 1, 2027

Restricted Shares exercised 8,069 shares Vested after one-year period ending April 1, 2026

Common Stock holdings after transactions 33,597 shares Direct ownership following April 1, 2026 transactions

Exercise price per share $0.00 per share Conversion of 8,069 Restricted Shares to Common Stock

Key Terms

Restricted Shares, vesting period, Treasury Regulation 1.409A-2, separation of service, +1 more

5 terms

Restricted Shares financial

"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

vesting period financial

"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027"

A vesting period is the set amount of time someone must wait before they fully own granted shares, stock options, or other equity tied to their work or an agreement; ownership increases gradually or in steps during that time. Investors care because vesting determines when insiders or employees can sell shares, which affects future supply of stock, company incentives and executive retention—think of it like unlocking ownership over installments rather than receiving it all at once.

Treasury Regulation 1.409A-2 financial

"subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2"

separation of service financial

"the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board"

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Form 4 Insider Transactions: What Each Field Means →

04/07/2026 - 07:45 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Temeng Kwaku

(Last)

(First)

(Middle)

6316 WINDFERN ROAD

(Street)

HOUSTON

TEXAS

77040

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Core Laboratories Inc. /DE/ [ CLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/01/2026		M		8,069	A	$0	33,597	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Shares	$0	04/01/2026		A		7,895		⁽¹⁾	⁽¹⁾	Common Stock	7,895	$0	7,895	D
Restricted Shares	$0	04/01/2026		M			8,069	⁽²⁾	⁽²⁾	Common Stock	8,069	$0	0	D

Explanation of Responses:

1. The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board.

2. The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.

	/s/ Mark Tattoli, Attorney-in-Fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Core Laboratories (CLB) director Temeng Kwaku report?

Director Temeng Kwaku reported equity compensation transactions, including a grant of 7,895 Restricted Shares and the exercise of 8,069 Restricted Shares into Common Stock at no cash price. These actions increased his direct Common Stock holdings to 33,597 shares.

How many Core Laboratories (CLB) Restricted Shares were granted to Temeng Kwaku?

Temeng Kwaku received a grant of 7,895 Restricted Shares. These shares are subject to a one-year vesting period ending April 1, 2027 and remain subject to a deferral election under Treasury Regulation 1.409A-2 before distribution as Common Stock.

When will Temeng Kwaku’s new Core Laboratories (CLB) Restricted Shares vest?

The newly granted 7,895 Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027. Vesting is subject to the terms of issuance and any deferral election made by the reporting person.

What happened to the previously granted Core Laboratories (CLB) Restricted Shares?

Previously granted Restricted Shares totaling 8,069 vested after a one-year period ending April 1, 2026. These vested Restricted Shares were then exercised or converted into 8,069 shares of Core Laboratories Common Stock at an exercise price of zero dollars per share.

How many Core Laboratories (CLB) Common Stock shares does Temeng Kwaku now hold?

After the April 1, 2026 transactions, Temeng Kwaku directly holds 33,597 shares of Core Laboratories Common Stock. This figure reflects his position following the exercise of 8,069 Restricted Shares into Common Stock disclosed in the filing.

How will Temeng Kwaku’s vested Core Laboratories (CLB) Restricted Shares be delivered?

The filing states vested Restricted Shares subject to deferral will be distributed as shares of Common Stock after Temeng Kwaku’s separation of service from the Board. This distribution timing follows his deferral election under Treasury Regulation 1.409A-2.